SC
KALV

Stephens Consulting’s KalVista Pharmaceuticals KALV Stock Holding History

Stephens Consulting’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$347 – 1592
2025
Q1 		$347 Buy
+30
New +$306 ﹤0.01% 1352

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Stephens Consulting's KALV Position: Q2 2025 in Review

Stephens Consulting sold out of KalVista Pharmaceuticals (KALV) in Q2 2025, closing a stake of 30 shares — an estimated $347 sold.

Stephens Consulting first reported a position in KALV in Q1 2025 and held it in 1 quarter. The position peaked at $347 in Q1 2025. 139 funds tracked by Wall St. Rank hold KALV as of Q2 2025.

  • Stephens Consulting reported no remaining KalVista Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 30 KalVista Pharmaceuticals shares in Q2 2025, an estimated $347.
  • Stephens Consulting first reported a position in KalVista Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's KalVista Pharmaceuticals position peaked at $347 in Q1 2025.
  • 139 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.